QUAD X Trademark

Trademark Overview


On Wednesday, April 19, 2023, a trademark application was filed for QUAD X with the United States Patent and Trademark Office. The USPTO has given the QUAD X trademark a serial number of 79379489. The federal status of this trademark filing is REGISTERED as of Tuesday, December 3, 2024. This trademark is owned by Elasmogen Ltd. The QUAD X trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical preparations for treatment of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases and eye diseases and disorders; biological preparations for treatment of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases and eye diseases and disorders; diagnostic preparations agents, and substances for medical purposes; anti-angiogenesis preparations; anti-cancer preparations; anti-inflammatory preparations; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, physiological disorders, hormonal disorders, inherited disease, single gene disorders, respiratory diseases, gastro-intestinal disorders, circulatory disorders, dermatological conditions, immuno-deficiencies, organ damage, cell proliferation, peripheral neurological disorders, genitourinary disorders, musculoskeletal disorders, and blood disorders; diagnostic reagents for medical use; DNA, antibodies and proteins for medic...

Medical and pharmacological research services; scientific and technological services, namely scientific research, analysis and testing in the field of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases, eye diseases and disorders, and intracellular delivery of pharmaceuticals and therapeutics; scientific research for medical purposes in the field of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases, eye diseases and disorders, and intracellular delivery of pharmaceuticals and therapeutics; pharmaceutical research and drug development services; pharmaceutical testing; research and development in the biotechnology field; research and development services in the field of antibodies; biotechnology research services; scientific research in the nature of conducting clinical trials for others; biological research, clinical research and medical research; providing scientific information about the results of clinical trials for pharmaceut...
quad x

General Information


Serial Number79379489
Word MarkQUAD X
Filing DateWednesday, April 19, 2023
Status700 - REGISTERED
Status DateTuesday, December 3, 2024
Registration Number7583012
Registration DateTuesday, December 3, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 1, 2024

Trademark Statements


Goods and ServicesPharmaceutical preparations for treatment of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases and eye diseases and disorders; biological preparations for treatment of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases and eye diseases and disorders; diagnostic preparations agents, and substances for medical purposes; anti-angiogenesis preparations; anti-cancer preparations; anti-inflammatory preparations; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, physiological disorders, hormonal disorders, inherited disease, single gene disorders, respiratory diseases, gastro-intestinal disorders, circulatory disorders, dermatological conditions, immuno-deficiencies, organ damage, cell proliferation, peripheral neurological disorders, genitourinary disorders, musculoskeletal disorders, and blood disorders; diagnostic reagents for medical use; DNA, antibodies and proteins for medical diagnosis purposes; DNA and antibodies and proteins that stimulate cells for medical use; DNA, antibodies and proteins for therapeutic use for treatment of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases and eye diseases and disorders; diagnostic preparations for medical purposes; reagents for medical use
Goods and ServicesMedical and pharmacological research services; scientific and technological services, namely scientific research, analysis and testing in the field of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases, eye diseases and disorders, and intracellular delivery of pharmaceuticals and therapeutics; scientific research for medical purposes in the field of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases, eye diseases and disorders, and intracellular delivery of pharmaceuticals and therapeutics; pharmaceutical research and drug development services; pharmaceutical testing; research and development in the biotechnology field; research and development services in the field of antibodies; biotechnology research services; scientific research in the nature of conducting clinical trials for others; biological research, clinical research and medical research; providing scientific information about the results of clinical trials for pharmaceutical products; research services in the field of diagnostic preparations; scientific laboratory services; custom design and development of biochemical assays; scientific and medical research laboratory services; research and development of new products for others; scientific research and analysis in the field of drug discovery; new product development in the field of pharmaceuticals for others; scientific advisory services, namely, medical advisory services related to pharmaceutical development and testing; scientific research consultancy in the field of cancer research, inflammatory disease research, auto-inflammatory disease research, autoimmune disease research, eye disease and disorder research, and intracellular delivery research of pharmaceuticals and therapeutics; scientific research and development; scientific research in the field of biotechnology and pharmaceuticals; consulting services for others in the field of design, planning, and implementation and project management of scientific research and clinical trials; providing scientific research information; technical advisory services relating to scientific and clinical research; provision of technical and scientific information and consultancy in relation to the aforesaid services

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, September 29, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, September 29, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameElasmogen Ltd
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressGB

Party NameElasmogen Ltd
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressGB

Party NameElasmogen Ltd
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressGB

Trademark Events


Event DateEvent Description
Tuesday, October 3, 2023APPLICATION FILING RECEIPT MAILED
Wednesday, January 17, 2024ASSIGNED TO EXAMINER
Thursday, September 28, 2023SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, September 29, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, January 17, 2024NON-FINAL ACTION WRITTEN
Thursday, January 18, 2024NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, February 1, 2024REFUSAL PROCESSED BY MPU
Thursday, February 1, 2024NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Monday, February 19, 2024REFUSAL PROCESSED BY IB
Monday, July 29, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, July 29, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, July 29, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, August 27, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 11, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, October 1, 2024PUBLISHED FOR OPPOSITION
Tuesday, October 1, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 3, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Monday, March 3, 2025FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Thursday, February 27, 2025NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Tuesday, December 3, 2024REGISTERED-PRINCIPAL REGISTER
Thursday, February 27, 2025NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB